• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Alumis Inc. - Common Stock (NQ:ALMS)

    27.05 -0.75 (-2.70%)
    Streaming Delayed Price Updated: 10:45 AM EDT, Aug 7, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Alumis Inc. - Common Stock

    < Previous 1 2 3 Next >
    News headline image
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
     
    Via Benzinga
    News headline image
    Tesla To $450? Here Are 10 Top Analyst Forecasts For Thursday ↗
     
    Via Benzinga
    News headline image
    ACELYRIN and Alumis Reaffirm Strategic and Financial Rationale of Proposed Merger
    From ACELYRIN, INC.
    Via GlobeNewswire
    News headline image
    ACELYRIN Determines Unsolicited Indication of Interest From Concentra Biosciences Not Reasonably Expected to Result in a Superior Proposal to Planned Alumis Merger
    From ACELYRIN, INC.
    Via GlobeNewswire
    News headline image
    ALMS Stock Earnings: Alumis Reported Results for Q2 2024 ↗
    Alumis just reported results for the second quarter of 2024. 
    Via InvestorPlace
    News headline image
    ACELYRIN Confirms Receipt of Unsolicited Indication of Interest from Concentra Biosciences
    From ACELYRIN, INC.
    Via GlobeNewswire
    News headline image
    What's going on in today's pre-market session ↗
    Discover the top movers in Friday's pre-market session and stay informed about market dynamics. 
    Via Chartmill
    News headline image
    12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
     
    Via Benzinga
    News headline image
    ALMS Stock Alert: Halper Sadeh LLC is Investigating Whether the Merger of Alumis Inc. is Fair to Shareholders
    From Halper Sadeh LLC
    Via Business Wire
    News headline image
    Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases
    From ACELYRIN, INC.
    Via GlobeNewswire
    News headline image
    12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
     
    Via Benzinga
    News headline image
    JB Hunt Transport Posts Weak Earnings, Joins JetBlue Airways And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗
     
    Via Benzinga
    News headline image
    Candel Therapeutics, 8x8 And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗
     
    Via Benzinga
    News headline image
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
     
    Via Benzinga
    News headline image
    Energizer, C3.ai, Insmed And Other Big Stocks Moving Higher On Tuesday ↗
     
    Via Benzinga
    News headline image
    This Alumis Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗
     
    Via Benzinga
    News headline image
    Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside ↗
    HC Wainwright has initiated coverage on Alumis, highlighting the biopharmaceutical company's lead drug candidate, ESK-001. The analyst notes ESK-001's superior clinical data compared to Bristol Myers... 
    Via Benzinga
    News headline image
    This Gilead Sciences Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗
     
    Via Benzinga
    News headline image
    Jim Cramer Says He's Buying 'Some Target,' But Dismisses SoundHound AI As 'Meme Stock' ↗
    Target (TGT) stock recommended by Jim Cramer at current price with plans to buy more. Merck (MRK) and Unity Software (U) also discussed. 
    Via Benzinga
    Topics Artificial Intelligence
    News headline image
    Alumis to Participate in Upcoming September Investor Conferences
    From Alumis Inc.
    Via GlobeNewswire
    News headline image
    Alumis Reports Second Quarter 2024 Financial Results and Highlights Recent Development and Corporate Achievements
    From Alumis Inc.
    Via GlobeNewswire
    News headline image
    Alumis Initiates ONWARD Phase 3 Clinical Program Evaluating ESK-001, an Oral TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis
    From Alumis Inc.
    Via GlobeNewswire
    News headline image
    Newly-Listed Psoriasis-Focused Alumis Attracts Analysts' Attention With Promising Lead Program And Modest Valuation ↗
    Guggenheim Partners initiated coverage on Alumis, highlighting its lead asset ESK-001, a TYK2 inhibitor for plaque psoriasis and systemic lupus erythematosus. With upcoming Phase 3 trials and no JAK... 
    Via Benzinga
    News headline image
    Ardent Health Slips After Downsized IPO ↗
    Shares of Ardent Health slipped in their trading debut on Thursday after the hospital operator reduced its initial public offering from its proposed size and priced below the marketed range. 
    Via Talk Markets
    News headline image
    Immune Disease-Focused Alumis Raises $250M In Downsized Initial Public Offering ↗
    Alumis priced its IPO at $16/share, raising $210 million with 13.13 million shares. Trading begins June 28, 2024. Alumis develops oral therapies for immune-mediated diseases, with its lead candidate... 
    Via Benzinga
    Topics Initial Public Offering
    < Previous 1 2 3 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.